Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae from urinary tract infections: Evolution of antimicrobial resistance and treatment options

Jiménez‐Guerra, Gemma; Heras-Cañas, Víctor; Molina, Lucía del Carmen Béjar; Sorlózano-Puerto, Antonio; Navarro-Marí, José María; Gutiérrez-Fernández, José

doi:10.1016/j.medcle.2018.01.014

Cited by 5 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of resistance to trimethoprim-sulfamethoxazole was 92.43%. This rate was consistent with those reported in other studies [14] [46]. However in a study conducted by Koita in 2019, had brought 97% resistance to trimethoprim/sulfamethoxazole [38].…”

Section: Discussionsupporting

confidence: 91%

Antibiotic Resistance in the Uropathogenic Enterobacteria Isolated from Patients Attending General Reference Hospital (GRH) of Niamey, Niger

Mohamed¹,

Dembélé²,

Salaou³

et al. 2023

OJMM

View full text Add to dashboard Cite

Background: Urinary tract infections (UTIs) are a frequent reason for consultation and lead to a significant and sometimes inappropriate prescription of antibiotics. The latter favors antibiotic resistance and an increase in mortality as well as the cost of treatment. The present study aims to contribute to the fight against antibiotic resistance of enterobacteria. Methods: This is a prospective study from January to December, 2021 in the Microbiology laboratory of the General Reference Hospital (GRH) of Niamey including 3369 urine samples. The antibiotic resistance of enterobacteria was determined How to cite this paper: Mohamed, A.H.,

show abstract

Section: Discussionsupporting

confidence: 91%

Antibiotic Resistance in the Uropathogenic Enterobacteria Isolated from Patients Attending General Reference Hospital (GRH) of Niamey, Niger

Mohamed¹,

Dembélé²,

Salaou³

et al. 2023

OJMM

View full text Add to dashboard Cite

show abstract

“…ESBL development can confer resistance against 3 rd and 4 th generation cephalosporins but this is much less frequent, as reflected in the markedly lower number of FEP-resistant than FEPsusceptible strains that grew on the medium. Although resistance to FEP is less common, it is not recommended as monotherapy against infection by ESBL enterobacteria to avoid spreading resistance, and it should only ever be used in combination with aminoglycosides or fluoroquinolones (24)(25)(26). Three of the carbapenemase-producing isolates (5.3% of the total with carbapenemases) did not grow on CHROMID ESBL medium, despite previously demonstrating resistance to carbapenems.…”

Section: Retrospective Studymentioning

confidence: 99%

High clinical impact of rapid susceptibility testing on CHROMID ESBL® medium directly from swabs

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Antibiotic resistance is a serious public health challenge exacerbated by the widespread use of β-lactam and glycopeptide antibiotics. The identification of resistances is crucial, and CHROMID ESBL medium has been developed to detect enterobacteria with extended-spectrum β-lactamases (ESBL). The objective of this study was to evaluate the potential of this medium to detect other types of resistant bacteria.Methods: Vancomycin, cefoxitin, imipenem, and cefepime disks were used to measure growth on CHROMID ESBL medium of β-lactam-resistant Gram-negative (83 with ESBL, 57 with carbapenemases, 35 with AmpC and 3 Stenotrophomonas maltophilia) and microorganisms and 21 vancomycin-resistant (vancoR) Enterococcus faecium] clinical isolates (retrospective study) and colonization by the aforementioned bacteria (prospective study), using 649 rectal swabs, 314 pharyngeal swabs, and 44 swabs from other localizations.Results: Retrospective study: species grown on the medium exhibited different colors. Growth on the medium was observed for: all ESBL enterobacteria, which were susceptible to imipenem and cefoxitin; 95% of isolates with carbapenemases, mostly resistant to imipenem; 80% of those with AmpC; 86% of vancoR E. faecium isolates; and 42% of vancoS E. faecalis isolates, with large growth inhibition halos around the vancomycin disk. Prospective study: vancoR E. faecium, ESBL Klebsiella, Pseudomonas with carbapenemases, A. baumannii (mostly from rectal swabs), S. maltophilia, Achromobacter xylosoxidans, and Burkholderia cenocepacia (mostly from pharyngeal swabs) were isolated from the 246 positive samples.Conclusions: CHROMID ESBL medium permitted the differential growth of Gram-negative bacteria, many with ESBL and carbapenemases. ESBL enterobacteria were susceptible to imipenem, carbapenemaseproducing microorganisms grew around the imipenem disk, and vancoR E. faecium was isolated on the medium. Results of the prospective study demonstrate the potential clinical relevance of this medium. S. maltophilia was more frequently detected with pharyngeal swabs and ESBL Klebsiella, A. baumannii, and Pseudomonas with rectal swabs.

show abstract

“…The treatment of E.Coli infection is challenging due to higher incidence of antibiotic resistance for several antibiotics (4,5) . Extended spectrum beta-lactamase (ESBL)-producing bacteria are resistant to different antibiotics (e.g., cephalosporins, penicillin, tazobactam/ piperacillin, co-trimoxazole, tetracyclines and fluoroquinolones) (6,7) .…”

Section: Introductionmentioning

confidence: 99%

Amikacin once every other day versus Daily Meropenem for Treatment of Urinary Tract Infection with Escherichia Coli

Ghorab,

Mostafa,

Alsakran

2024

SJMS

View full text Add to dashboard Cite

Background and Aim: Urinary tract infection (UTI) is a common medical challenge, especially in the light of increased antibiotic resistance. This work aimed to compare between amikacin (3 doses, once each other day) with a daily dose of meropenem (once daily for seven days) for the treatment of urinary tract infection caused by Escherichia Coli. Patients and Methods: 70 patients with confirmed UTI infection by E. Coli were included and divided for two groups. The first was treated by amikacin 15mg/kg once every 48 hours for seven days. The second group was treated by meropenem 1 g three times daily for one week. Then, urinary culture and sensitivity was re-performed and tested against the commonest panel of antibiotics. The clinical manifestations were documented before treatment and one week after treatment. Results: There was no significant difference between groups regarding patient demographics or manifestations of UTI. 54.3% in amikacin and 65.7% in meropenem groups reported previous UTI. The clinical manifestations of UTI include dysuria, frequent urination, flank pain, abdominal pain, fever and suprapubic pain. The treatment was associated with eradication of E. Coli in 60.0% and 54.3% in Amikacin and meropenem respectively, with no significant differences between groups at the end of the first week and at that time, the most sensitive drugs were nitrofurantoin (34.3%) followed by meropenem (22.9%) and amikacin (18.6%). However, the highest resistance was registered for cefepime and cefotaxime (41.4%) followed by ceftazidime-clavulanic acid (40.0%). Clinical manifestations of UTI were significantly reduced in both groups one week after treatment with no significant differences between groups. Conclusion: Amikacin could be considered as is an effective and safe alternative to meropenem for treatment of UTI due to E. Coli.

show abstract

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae from urinary tract infections: Evolution of antimicrobial resistance and treatment options

Cited by 5 publications

References 9 publications

Antibiotic Resistance in the Uropathogenic Enterobacteria Isolated from Patients Attending General Reference Hospital (GRH) of Niamey, Niger

Antibiotic Resistance in the Uropathogenic Enterobacteria Isolated from Patients Attending General Reference Hospital (GRH) of Niamey, Niger

High clinical impact of rapid susceptibility testing on CHROMID ESBL® medium directly from swabs

Amikacin once every other day versus Daily Meropenem for Treatment of Urinary Tract Infection with Escherichia Coli

Contact Info

Product

Resources

About